Premium
Monoamine Oxidase Inhibition for Tobacco Pharmacotherapy
Author(s) -
George TP,
Weinberger AH
Publication year - 2008
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/sj.clpt.6100474
Subject(s) - bupropion , varenicline , monoamine oxidase , medicine , pharmacology , nicotine replacement therapy , addiction , smoking cessation , pharmacotherapy , nicotine , tobacco harm reduction , drug , psychiatry , tobacco use , environmental health , population , biology , biochemistry , pathology , enzyme
Tobacco addiction is the most significant preventable cause of morbidity and mortality in the Western world, with >430,000 deaths annually from tobacco‐related diseases being reported in the United States. 1 Although effective treatments are available for cessation of smoking (e.g., nicotine replacement therapies, sustained‐release bupropion and varenicline), they do not work for all smokers. Therefore the development of more effective medications for treating tobacco dependence, based on novel mechanisms, is a high priority. 2 This article reviews the links between smoking and monoamine oxidase (MAO) inhibition, which could lead to the development of novel pharmacotherapies to treat tobacco dependence. Clinical Pharmacology & Therapeutics (2008); 83 , 4, 619–621. doi: 10.1038/sj.clpt.6100474